Adicet Bio
ACET
Adicet Bio (ACET) news
Recent news
Air Canada adds Seville to growing European network
AInvest Wire · 1d agoADICet Bio, Inc.: Wedbush raises target price to $28 from $25
AInvest Wire · Sep 29, 2026ADICet Bio, Inc.: H.C. Wainwright raises target price to $34 from $27
AInvest Wire · Sep 28, 2026ADICet Bio, - Anticipated clinical data update in lupus nephritis/systemic lupus erythematosus in mid 2027
Adicet Bio, Inc. (NASDAQ: ACET) is preparing to release clinical data for prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus (SLE) in mid-2027. The company has previously reported topline data for 22 SLE patients in September 2026, which is expected to inform the design…
AInvest Wire · Sep 28, 2026ADICet Bio, - Plans to initiate pivotal lupus nephritis trial start-up activities in Q4 2026
AInvest Wire · Sep 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.